Abionic has signed an agreement with Genentech to develop and provide rapid Point-of-Care tests for Asthma in the US. The technical basis is Abionic’s POC abioSCOPE platform, a compact, ultra-fast medical device powered by a patented nanofluidic technology.
In the U.S., 25 million people suffer from asthma, the majority of which have allergic asthma. Allergic asthma can be life threatening. This makes access to prompt, accurate diagnosis and appropriate treatment vital. Abionic's 5-minute point-of-care (POC) test will help physicians determine both total IgE as well as specific IgE levels to 5 major perennial allergens associated with allergic asthma.
For the development and the launch Abionic has teamed up with Genentech. They plan to provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE platform. Abionic’s POC abioSCOPE, a compact, ultra-fast medical device powered by a patented nanofluidic technology, determines blood levels of immunoglobulin E (IgE), an underlying cause of allergic asthma. The platform provides lab-quality results in five minutes from a single drop of blood at the POC, enabling rapid diagnosis and the possibility of immediate treatment initiation.
Under the terms of the agreement, Abionic will carry out all pre-market process requirements for a specific Asthma Test Panel to quantify total IgE as well as IgE levels to 5 major perennial allergens associated with allergic asthma. Genentech will fund all clinical and regulatory costs for the tests.
“The agreement with Genentech, a leader in developing novel medicines in respiratory diseases including allergic asthma, is a great step towards more personalized and precise diagnostics,” commented Nicolas Durand, PhD, Chief Executive Officer of Abionic.